Atlas Trials

A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations

Clinical trial NCT03434418 · COMPLETED

Trial details

NCT number
NCT03434418
Sponsor
Duke University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non Small Cell Lung Cancer
Start date
2018-06-30
Primary completion
2022-10-12
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.